SRNE - Sorrento stock rises after FDA gives nod to begin phase 2 study of abivertinib to treat prostate cancer

Sorrento Therapeutics (NASDAQ:SRNE +5.6%) said on Tuesday it had received clearance from the FDA for its application to begin trial for a Phase 2 study of Abivertinib to be conducted in participants with metastatic castrate resistant prostate cancer ((mCRPC)) at multiple centers in the United States. The study, dubbed Maverick, will enroll participants with both abiraterone-naïve and abiraterone-progressing mCRPC. The main goal of the study is to evaluate the efficacy of Abivertinib with prostate cancer therapy abiraterone and  assess 6-month radiographic progression-free survival. The primary endpoint would be the 6-month radiographic progression-free survival defined as a percent of subjects alive and without progression. The global market for CRPC for 2021 was $2.7 billion, with the U.S. accounting for 67%, the company said.

For further details see:

Sorrento stock rises after FDA gives nod to begin phase 2 study of abivertinib to treat prostate cancer